XTNT
ANALYST COVERAGE5 analysts
BUY
+220.6%upside to target
Buy
480%
Hold
120%
4 Buy (80%)1 Hold (20%)0 Sell (0%)
Full report →
Key MetricsTTM
Market Cap$65.62M
Revenue TTM$121.91M
Net Income TTM$1.83M
Free Cash Flow$7.77M
Gross Margin62.3%
Operating Margin2.7%
Net Margin1.5%
Return on Equity3.7%
Return on Assets2.3%
Debt / Equity0.32
Current Ratio3.34
EPS TTM$0.01
PRICE
Prev Close
0.47
Open
0.47
Day Range0.47 – 0.47
0.47
0.47
52W Range0.44 – 0.95
0.44
0.95
5% of range
VOLUME & SIZE
Avg Volume
153.4K
FUNDAMENTALS
P/E Ratio
46.8x
Premium valuation
EPS (TTM)
Div Yield
No dividend
Beta
0.29
Low vol
TECHNICAL
RSI (14)
34
Bearish momentum
Upcoming Events
EEarnings Report
Tomorrow
May 22
DEx-Dividend
In 90 days
Aug 19
PDividend Pay
In 120 days
Sep 18

XTNT News

About

xtant medical (nyse mkt: xtnt) develops, manufactures and markets regenerative medicine products and medical devices for domestic and international markets. xtant products serve the specialized needs of orthopedic and neurological surgeons, including orthobiologics for the promotion of bone healing, implants and instrumentation for the treatment of spinal disease, tissue grafts for the treatment of orthopedic disorders, and biologics to promote healing following cranial, and foot and ankle surgeries. with core competencies in both biologic and non-biologic surgical technologies, xtant can leverage its resources to successfully compete in global neurological and orthopedic surgery markets. for further information, please visit xtantmedical.com.

CEO
Sean Browne
Scott C. NeilsChief Financial Officer
Mark SchallenbergerChief Operations Officer
Sean E. BrownePresident, Chief Executive Officer & Director
Catherine LundyVice President of Human Resources